Combined half-body irradiation and chemotherapy for two dogs with relapsed high-grade B-cell lymphoma.
1/5 보강
This report describes two dogs with high-grade multicentric B-cell lymphoma that relapsed 3 months after completing a 6-month-long chemotherapy regimen with L-asparaginase, cyclophosphamide, doxorubic
APA
Goto S, Watanabe S, et al. (2026). Combined half-body irradiation and chemotherapy for two dogs with relapsed high-grade B-cell lymphoma.. The Journal of veterinary medical science, 88(1), 37-40. https://doi.org/10.1292/jvms.25-0373
MLA
Goto S, et al.. "Combined half-body irradiation and chemotherapy for two dogs with relapsed high-grade B-cell lymphoma.." The Journal of veterinary medical science, vol. 88, no. 1, 2026, pp. 37-40.
PMID
41183984 ↗
Abstract 한글 요약
This report describes two dogs with high-grade multicentric B-cell lymphoma that relapsed 3 months after completing a 6-month-long chemotherapy regimen with L-asparaginase, cyclophosphamide, doxorubicin, vincristine, and prednisolone (L-CHOP). Both were re-treated with L-CHOP, achieving complete remission (CR) before undergoing sequential half-body irradiation (HBI; 6 Gy per fraction to cranial and caudal body, 2 weeks apart). Caudal HBI caused grade 3 gastrointestinal toxicity in both dogs and grade 3 thrombocytopenia in one; however, both remain in CR at the time of writing this report (i.e., 483 and 490 days post-relapse). These findings suggest that combining HBI with chemotherapy may offer benefits in relapsed canine lymphoma, especially when dogs are in CR at the time of HBI.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Animals
- Dogs
- Antineoplastic Combined Chemotherapy Protocols
- Asparaginase
- Combined Modality Therapy
- Cyclophosphamide
- Dog Diseases
- Doxorubicin
- Hemibody Irradiation
- Lymphoma
- B-Cell
- Neoplasm Recurrence
- Local
- Prednisone
- Vincristine
- chemotherapy
- half-body irradiation
- multicentric lymphoma
- recurrence
- second remission
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- SpNeigh: spatial neighborhood and differential expression analysis for high-resolution spatial transcriptomics.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- The tumor microenvironment as a key regulator of radiotherapy response.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.